Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients.

Yohei KawaguchiRisa ShimauchiNobuhiro NishiboriKiyohito KawashimaSo OshitaniAtsushi FujiyaTaiga ShibataNorimi OhashiKentaro IzumiWataru NishieHiroshi ShimizuHiroshi ArimaHiroshi Sobajima

Published in: Journal of diabetes investigation (2018)

The positive rate of anti-BP180NC16a antibody was lower in BP patients with DPP4I than without DPP4I, regardless of type 2 diabetes mellitus. The antibody titer was low in both the overall and type 2 diabetes mellitus populations. The prevalence of BP in 9,304 patients receiving DPP4Is was 0.0859%, which is higher than that in the general population. As DPP4Is are common diabetes treatments, we must be aware of the risk of BP.

Keyphrases

glycemic control
end stage renal disease
type diabetes
newly diagnosed
ejection fraction
chronic kidney disease
cardiovascular disease
prognostic factors
adipose tissue
skeletal muscle